Susan Galbraith, AstraZeneca oncology chief
After 18 years in development, AstraZeneca’s CTLA-4 antibody gets the red carpet treatment at the FDA
After a decade, a second CTLA-4 antibody may finally be on its way to approval.
AstraZeneca announced Monday that the FDA had given priority review …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
